Real‐world analysis of CPX ‐351 in AML ‐ MR : A multicentre study from the MARROW consortium

Documenti analoghi

• CREST‐UK: Real‐world effectiveness, safety and outpatient delivery of CPX‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK
  di: Priyanka Mehta, et al.
  Pubblicazione: (2024)
• CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study
  di: Chezi Ganzel, et al.
  Pubblicazione: (2024)
• Case of CPX ‐351‐Induced Purpuric Rash Occurred in a Patient With Pure Erythroid Leukemia
  di: Nobuyuki Asano, et al.
  Pubblicazione: (2025)
• Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
  di: Fabio Guolo, et al.
  Pubblicazione: (2025)
• A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
  di: Tapan M. Kadia, et al.
  Pubblicazione: (2025)